Answers are grounded in this paper and cite their sources.
Shows reduced tumor growth in glioblastoma via engineered bacteria targeting metabolic pathways.
76 Background: Glioblastoma (GBM) is the most aggressive primary brain tumor with limited therapeutic options and poor prognosis. Metabolic reprogramming is a hallmark of GBM, yet the role of D-lactate, an understudied stereoisomer of lactate, remains elusive. While L-lactate has been extensively characterized, we identified D-lactate as a systemically circulating oncometabolite that disrupts intestinal homeostasis via the gut-brain axis, representing an unexplored therapeutic vulnerability in GBM. Methods: Through untargeted metabolomics of patient-derived GBM stem-like cells and brain organoid co-culture models, we characterized D-lactate as a key tumor-secreted metabolite. We screened human and murine gut microbiota to isolate D-lactate-metabolizing bacteria, cloned six highly active D-lactate dehydrogenases (LDHDs), and engineered probiotic Escherichia coli Nissle 1917 (EcN) to express optimal variants. Lipid-coated therapeutic bacteria (Lipo-EcN-LDHD) were developed to enhance gastric stability and intestinal colonization. Therapeutic efficacy was evaluated in orthotopic GBM xenograft models using bioluminescence imaging, survival analysis, histopathology, and metagenomic sequencing. Results: GBM-bearing mice exhibited ~4-fold elevation in serum D-lactate (~150 μM) compared to controls, accompanied by intestinal shortening and dysbiosis. Natural D-lactate-metabolizing bacteria significantly suppressed tumor growth and prolonged survival. Enzymatic characterization identified MeLDHD3 as the most catalytically efficient variant. Oral administration of Lipo-EcN-MeLDHD3 achieved robust intestinal colonization, reduced systemic D-lactate levels, significantly inhibited orthotopic tumor growth ( P <0.01), and prolonged survival ( P <0.05). Treatment restored gut microbiota homeostasis, reduced tumor Ki67 proliferation index, and attenuated D-lactate-mediated immunosuppressive microenvironment. Conclusions: This study establishes D-lactate as a novel metabolic target in GBM and demonstrates the first synthetic biology-inspired "gut-heals-brain" therapeutic strategy. Engineered probiotic EcN expressing LDHD enables non-invasive, sustained systemic clearance of tumor-derived D-lactate, offering a safe, precision metabolic intervention for GBM. This platform validates the gut-brain axis as a druggable conduit for brain tumor therapy and provides a transformative paradigm for treating metabolically driven malignancies.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: